Brief: FDA Grants Orphan Drug Designation To Brain Cancer Treatment
02/03/2023 12:56
March 2 (Reuters) - Genenta Science SPA K5Fy.F :
* FDA GRANTS ORPHAN DRUG DESIGNATION TO TEMFERON FOR
TREATMENT OF
GLIOBLASTOMA MULTIFORME
Source text for Eikon: ID:nGNX2n5Czm
Further company coverage: K5Fy.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Genenta Science SpA
See all newsBrief: Genenta & Anemocyte Announce Strategic Partnership To Advance Off-The-Shelf LVV Plasmid Dna Production
Brief: Genenta Science SpA -Entered Amendment To ATM Sales Agreement Dated April 26
Brief: Genenta To Provide Update On Lead Product Temferon™
Genenta Science rises on FDA's "orphan drug" tag for brain cancer drug
Brief: FDA Grants Orphan Drug Designation To Brain Cancer Treatment